In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Nu Skin Enterprises, Inc (NYSE: NUS) closed at $11.37 down -2.99% from its previous closing price of $11.72. In other words, the price has decreased by -$2.99 from its previous closing price. On the day, 0.72 million shares were traded. NUS stock price reached its highest trading level at $12.03 during the session, while it also had its lowest trading level at $11.2964.
Ratios:
For a deeper understanding of Nu Skin Enterprises, Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.12 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.60. For the most recent quarter (mrq), Quick Ratio is recorded 1.38 and its Current Ratio is at 2.01. In the meantime, Its Debt-to-Equity ratio is 0.39 whereas as Long-Term Debt/Eq ratio is at 0.35.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for the company, Jefferies on January 31, 2023, Downgraded its rating to Hold and sets its target price to $39 from $43 previously.
BofA Securities Upgraded its Underperform to Neutral on October 02, 2020, whereas the target price for the stock was revised from $54 to $58.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 04 ’25 when Nathanson Laura sold 6,489 shares for $12.22 per share. The transaction valued at 79,296 led to the insider holds 33,149 shares of the business.
Clark Chayce David sold 20,000 shares of NUS for $239,400 on Sep 03 ’25. The EVP and General Counsel now owns 233,140 shares after completing the transaction at $11.97 per share. On Sep 04 ’25, another insider, Nathanson Laura, who serves as the Director of the company, bought 6,489 shares for $12.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NUS now has a Market Capitalization of 562789056 and an Enterprise Value of 635895040. As of this moment, Nu’s Price-to-Earnings (P/E) ratio for their current fiscal year is 5.67, and their Forward P/E ratio for the next fiscal year is 7.29. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.35 while its Price-to-Book (P/B) ratio in mrq is 0.71. Its current Enterprise Value per Revenue stands at 0.391 whereas that against EBITDA is 4.054.
Stock Price History:
The Beta on a monthly basis for NUS is 0.97, which has changed by 0.77656245 over the last 52 weeks, in comparison to a change of 0.17904854 over the same period for the S&P500. Over the past 52 weeks, NUS has reached a high of $14.62, while it has fallen to a 52-week low of $5.32. The 50-Day Moving Average of the stock is 2.20%, while the 200-Day Moving Average is calculated to be 37.44%.
Shares Statistics:
For the past three months, NUS has traded an average of 581.00K shares per day and 776510 over the past ten days. A total of 49.50M shares are outstanding, with a floating share count of 47.60M. Insiders hold about 3.84% of the company’s shares, while institutions hold 73.65% stake in the company. Shares short for NUS as of 1757894400 were 2232872 with a Short Ratio of 3.84, compared to 1755216000 on 1831760. Therefore, it implies a Short% of Shares Outstanding of 2232872 and a Short% of Float of 4.5700002.
Dividends & Splits
According to the company, the forward annual dividend rate for NUS is 0.24, from 0.24 in the trailing year. Against a Trailing Annual Dividend Yield of 0.020477815. The stock’s 5-year Average Dividend Yield is 4.58.
Earnings Estimates
. The current rating of Nu Skin Enterprises, Inc (NUS) reflects the combined expertise of 1.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.33, with high estimates of $0.33 and low estimates of $0.33.
Analysts are recommending an EPS of between $1.26 and $1.26 for the fiscal current year, implying an average EPS of $1.26. EPS for the following year is $1.56, with 1.0 analysts recommending between $1.56 and $1.56.
Revenue Estimates
A total of 1 analysts believe the company’s revenue will be $374.2M this quarter.It ranges from a high estimate of $374.2M to a low estimate of $374.2M. As of. The current estimate, Nu Skin Enterprises, Inc’s year-ago sales were $430.14MFor the next quarter, 1 analysts are estimating revenue of $392.1M. There is a high estimate of $392.1M for the next quarter, whereas the lowest estimate is $392.1M.
A total of 1 analysts have provided revenue estimates for NUS’s current fiscal year. The highest revenue estimate was $1.52B, while the lowest revenue estimate was $1.52B, resulting in an average revenue estimate of $1.52B. In the same quarter a year ago, actual revenue was $1.73BBased on 1 analysts’ estimates, the company’s revenue will be $1.53B in the next fiscal year. The high estimate is $1.53B and the low estimate is $1.53B.
